Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7807381 | 0.94 | MAPT (0.32) | MIFMAPTLMNAPOLBALDH1A1 | |
| SCHEMBL661855 | 0.90 | LMNA (0.33) | MIFMAPTLMNAPOLB | |
| SCHEMBL11213610 | 0.66 | KMT2A (0.49) | MIFMAPTLMNAPOLBALDH1A1 | |
| SCHEMBL6694136 | 0.66 | ALDH1A1 (0.56) | MIFMAPTLMNAPOLBALDH1A1 | |
| SCHEMBL1847472 | 0.62 | DAO (0.48) | MIFMAPTPOLBALDH1A1KMT2A | |
| SCHEMBL8634167 | 0.61 | MIF (0.46) | MIFMAPTLMNAALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL8634171 | 0.61 | DAO (0.47) | MIFMAPTPOLBALDH1A1KMT2A | |
| SCHEMBL28263654 | 0.61 | SMN1; SMN2 (0.50) | MIFMAPTLMNAALDH1A1KMT2A | |
| SCHEMBL2789975 | 0.61 | MAPT (0.48) | MIFMAPTLMNAALDH1A1KMT2A | |
| SCHEMBL1844829 | 0.60 | MIF (0.43) | MIFMAPTLMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | claimed |
| EP-2427432-A2 | NOVEL HETEROCYCLIC COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2012-03-14 | — | — | EP | disclosed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
| WO-2010128528-A2 | NOVEL HETEROCYCLIC COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | MIF 1807/4885MAPT 61/4885LMNA 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.